关于我们
关于HLB
领导寄语
沿革
地位
集团
制药,生物科技
造船
生活·健康·餘暇活動
金融
事业
制药,生物科技
细胞毒性药物
靶向治疗药物
免疫疗法
特殊船舶
GRE PIPE事业
投资者关系
股价信息
公司公告
公关
IR LETTER
报刊
资料室
职业
招聘
中文
韩文
英文
home
Title + Content
主题+内容
主题
内容
探索
顺序
主题
题目
日子
148
HLB increases stake in HLB Therapeutics to 6.25%
admin
2024.03.20
147
HLB Pharmaceutical secures domestic rights to riboceranib+camrelizumab combo
admin
2024.03.08
146
US FDA approval imminent… HLB affiliates are all strong
admin
2024.02.29
145
FDA Approved 48.65% More Novel Drugs in 2023. HLB Says 'Definitely Achieve It This Year'
admin
2024.01.08
144
Rivoceranib Combination Shows Efficacy in Neoadjuvant Chemotherapy for GC Patients
admin
2024.01.05
143
HLB Panagene Receives Export Licenses for Two Cancer-Related Mutation Test Kits
admin
2023.12.27
142
HLB's US Subsidiary Signs Licensing Consultancy Agreement with European Pharma for Liver Cancer Drug
admin
2023.12.27
141
HLB's shareholders approve plan to move to main bourse from KOSDAQ
admin
2023.12.22
140
HLB Becomes a Foreign Investor Favorite After Short-Selling Ban
admin
2023.12.14
139
[ESMO 2023] ‘HLB will apply for European authorization for rivoceranib this year’
admin
2023.10.23
1
2
3
4
5
6
7
8
9
10
>
>>